Table 1.
Baseline Clinicopathological Characteristics of Patients with Endometrioid Endometrial Carcinoma (n = 622).
| Characteristic | n (%) |
|---|---|
| Age | |
| <60 years | 396 (63.7) |
| ≥60 years | 226 (36.3) |
| Median age (years) | 56 (range 24–87) |
| Body Mass Index (BMI) | |
| Mean BMI (kg/m2) | 32.8 ± 7.3 |
| Underweight | 7 (1.1) |
| Normal weight | 64 (10.3) |
| Overweight | 143 (23.0) |
| Obesity class I | 184 (29.6) |
| Obesity class II | 135 (21.7) |
| Obesity class III | 89 (14.3) |
| Menopausal status | |
| Pre-menopausal | 169 (27.2) |
| Post-menopausal | 453 (72.8) |
| FIGO Stage (2009) | |
| IA | 275 (44.2) |
| IB | 169 (27.2) |
| II | 68 (10.9) |
| IIIA | 38 (6.1) |
| IIIB | 14 (2.3) |
| IIIC | 36 (5.8) |
| IV | 22 (3.5) |
| Myometrial invasion | |
| <50% | 325 (52.3) |
| ≥50% | 297 (47.7) |
| LVSI | |
| Negative | 316 (50.8) |
| Focal | 25 (4.0) |
| Diffuse | 27 (4.3) |
| Unknown/Missing | 253 (40.7) |
| ER status | |
| Positive | 135 (92.5) |
| Negative | 11 (7.5) |
| Unknown/Missing | 476 (76.5 of total cohort) |
Table 2.
Treatment Characteristics.
| Characteristic | n (%) |
|---|---|
| Surgical Procedure | |
| TAH + BSO | 587 (94.4) |
| Subtotal hysterectomy | 9 (1.4) |
| No surgery | 26 (4.2) |
| Lymph Node Dissection | |
| Yes | 113 (18.2) |
| No | 509 (81.8) |
| Nodal Status | |
| Negative | 586 (94.2) |
| Positive | 36 (5.8) |
| Adjuvant Radiotherapy (EBRT) | |
| Yes | 356 (57.2) |
| No | 266 (42.8) |
| Brachytherapy | |
| Yes | 377 (60.6) |
| No | 245 (39.4) |
| Concurrent Chemotherapy | |
| Yes | 595 (95.7) |
| No | 27 (4.3) |
| Induction/Adjuvant Chemotherapy | |
| Yes | 520 (83.6) |
| No | 102 (16.4) |
| Outcome | |
| Alive | 561 (90.2) |
| Dead | 61 (9.8) |
| Relapse Status | |
| No | 510 (82.0) |
| Yes | 112 (18.0) |
| Treatment at Relapse | |
| Chemotherapy | 60 (9.6) |
| Radiotherapy | 18 (2.9) |
| Surgery | 11 (1.8) |
| Supportive care | 17 (2.7) |
| Not applicable | 514 (82.6) |
Figure 1.
Overall survival stratified by FIGO stage.
Kaplan–Meier curves illustrating overall survival (OS) according to FIGO stage (I–IV). Survival outcomes differed significantly across stages (log-rank p < 0.0001), with progressively worse survival observed with advancing stage. Patients with stage I disease demonstrated the most favorable survival, whereas stage IV disease was associated with the poorest outcomes. Tick marks represent censored observations, and numbers at risk at prespecified time intervals are displayed below the x-axis.
Figure 2.
Overall survival stratified by FIGO stage III subgroups (IIIA, IIIB, IIIC).
Kaplan–Meier curves demonstrating overall survival among patients with stage III endometrioid endometrial carcinoma, subclassified into stage IIIA, IIIB, and IIIC. Stage IIIC shows comparatively poorer survival outcomes, with an estimated median overall survival of approximately 69 months. Survival differences between subgroups were statistically significant (log-rank p = 0.0055). Tick marks indicate censored observations. The number of patients at risk at specified time intervals is displayed below the plot.
Figure 3.
Overall survival stratified by nodal status.
Kaplan–Meier curves demonstrating overall survival (OS) according to nodal status in patients with endometrioid endometrial carcinoma. Patients with node-positive disease exhibited significantly inferior survival compared with node-negative patients (log-rank p < 0.0001). The median OS for the node-positive cohort was approximately 69 months, while median OS was not reached in the node-negative group. Tick marks indicate censored observations. Numbers at risk at prespecified time intervals are provided below the x-axis.
Table 3.
Univariate Cox Regression Analysis for Overall Survival.
| Variable | HR (95% CI) | p-value |
|---|---|---|
| FIGO Stage | <0.001 | |
| Stage I | Reference | |
| Stage II | 2.26 (1.07–4.79) | |
| Stage III | 3.08 (1.68–5.63) | |
| Stage IV | 6.69 (2.92–15.3) | |
| Nodal Status | <0.001 | |
| Negative | Reference | |
| Positive | 4.98 (2.64–9.40) | |
| Tumor Grade | 0.072 | |
| Grade I | Reference | |
| Grade II | 1.09 (0.62–1.90) | |
| Grade III | 2.40 (1.17–4.93) | |
| Myometrial Invasion | 0.101 | |
| <50% | Reference | |
| ≥50% | 1.53 (0.92–2.54) | |
| Age (per year) | 1.02 (0.99–1.04) | 0.140 |
| BMI (per unit) | 0.94 (0.90–0.97) | <0.001 |
| Menopausal Status | 0.124 | |
| Pre-menopausal | Reference | |
| Post-menopausal | 1.56 (0.87–2.79) |
Table 4.
Multivariate Cox Regression Analysis for Overall Survival.
| Variable | HR (95% CI) | p-value |
|---|---|---|
| FIGO Stage | ||
| Stage I | Reference | |
| Stage II | 2.46 (1.14–5.31) | 0.022 |
| Stage III | 1.14 (0.42–3.06) | 0.800 |
| Stage IV | 5.82 (2.43–13.9) | <0.001 |
| Nodal Status | ||
| Negative | Reference | |
| Positive | 5.89 (2.00–17.3) | 0.001 |
| Tumor Grade | ||
| Grade I | Reference | |
| Grade II | 0.71 (0.39–1.31) | 0.300 |
| Grade III | 1.18 (0.52–2.68) | 0.700 |
| Age (per year) | 1.03 (1.00–1.06) | 0.023 |
| BMI (per unit) | 0.95 (0.91–0.99) | 0.009 |
| Myometrial Invasion | ||
| <50% | Reference | |
| ≥50% | 1.02 (0.56–1.84) | 0.940 |